InvestorTalk Alert: Brent Willis from Voyageur Pharmaceuticals Ltd. to host on Tuesday, December 9, 2025

InvestorNews.com is pleased to announce an upcoming InvestorTalk scheduled for tomorrow, Tuesday, December 9, at 9:00 AM EST, featuring Brent Willis, President, CEO, and Director, Voyageur Pharmaceuticals Ltd. (TSXV: VM). To participate in this engaging discussion, please click here

Voyageur Pharmaceuticals is developing barium and iodine Active Pharmaceutical Ingredients for high-performance, cost-effective imaging contrast agents. With a goal of vertical integration, the company plans to produce its own barium and iodine and work with Canadian GMP manufacturers to validate products and generate early sales. Voyageur intends to grow into a high-margin manufacturer of radiology drugs, supported by its 100% ownership of the high-grade Frances Creek barite project—positioned as a superior alternative to synthetic pharmaceutical barium. Its vision is to become the first fully integrated radiology contrast media producer, controlling raw materials through to final drug production under its motto: “From the Earth to the Bottle.”

In preparation for tomorrow’s InvestorTalk, here are some recent news releases from Voyageur Pharmaceuticals for your review, which are listed below:

• November 7, 2025 – Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion — click here
• October 29, 2025 – Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX – click here
• October 23, 2025 – Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion  – click here

We found the October 29^th news release titled, “Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX” particularly noteworthy and here are 5 key data points from it:

• Distribution Agreement Signed with Phalanx – Voyageur has entered into a non-exclusive distribution and wholesale agreement with Mexico-based Phalanx following a 2025 LOI.
• Mexican Market Entry for Barium Contrast Media – Phalanx will register and distribute Voyageur’s barium sulfate contrast products in Mexico through its established network.
• Strategic Partnership to Support Regulatory and Commercialization Efforts – Both companies will collaborate to secure regulatory approvals, expand market access, and drive commercialization in Mexico and Latin America.
• Phalanx Brings 20+ Years of Contrast Media Expertise – The distributor specializes in Latin American healthcare markets with strong experience in iodine and gadolinium contrast media, logistics, and market strategy.
• Milestone in Voyageur’s Global Expansion Strategy – The agreement supports Voyageur’s international growth plan, targeting high-demand, underserved markets with long-term sales potential pending regulatory approval.

For more information on Voyageur Pharmaceuticals Ltd., click here

For more information on the InvestorTalk pre-market series, go to InvestorTalk.com.